Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Google Joins Novartis Backing Medicxi’s New $300m Late-Stage Fund

Executive Summary

Alphabet's Verily Life Sciences intends to increase its exposure to European biotech by joining Novartis and the European Investment Fund as cornerstone investors in Medicxi Growth 1 (MG1), a $300m fund launched by VC firm Medicxi to focus on late-stage private life science companies.

You may also be interested in...



Medicxi Closes €400m Medicxi III Biotech Fund In 6 Weeks

European life sciences investment firm Medicxi shows institutional investor appetite for life sciences venture capital is still strong as it secures €400m in an over-subscribed offering.

What Was On Hold Is New Again As Impact Raises $22.5m For Fedratinib

Medicxi-funded Impact Biomedicines gave Sanofi a stake in the start-up to acquire fedratinib and bring the JAK2 inhibitor, which was placed on a clinical hold in 2013, to patients who are out of options.

Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter

Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel